Iterum Therapeutics (ITRM)

• Market cap: $48.7M
• 1 day: 1.14%
• 5 days: -1.12%
• 1 month: 8.59%
• 3 months: 68.57%
• 6 months: 53.91%
• Year to date: -10.61%
• 1 year: 5.99%
• 5 years: -95.56%
• 10 years: -99.08%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Employees: 14

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

344% more capital invested

Capital invested by funds: $501K [Q2] → $2.22M (+$1.72M) [Q3]

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

20% more funds holding

Funds holding: 15 [Q2] → 18 (+3) [Q3]

6.35% more ownership

Funds ownership: 2.64% [Q2] → 8.99% (+6.35%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2